2024-04-24 19:19:03
(ANSA) – ROME, APRIL 24 – The European Commission has granted marketing authorization (Aic) for Lilly’s tirzepatide injectable solution in the KwikPen pre-filled multi-dose device. This was announced by the pharmaceutical company Lilly, specifying that the medicine has been authorized for two indications: the treatment of adults with inadequately controlled type 2 diabetes mellitus who cannot take metformin or in addition to other medicines for the treatment of diabetes, in association with diet and exercise; weight management of obese or overweight adults with at least one weight-related comorbidity, in addition to a low-calorie diet and increased physical activity.
KwikPen was launched by Lilly in 2008 and is already used by millions of type 2 diabetes patients around the world.
The European Commission’s decision regarding the use of KwikPen will allow tirzepatide to be brought to a greater number of patients and more quickly: “Diabetes and obesity are chronic diseases with a huge impact on people’s health and quality of life. – said Veronica Rogai, Associate VP-Medical Italy Hub Lilly – We want to do everything we can to ensure that our innovative medicines can reach the patients who need them.
We recognize that there is significant unmet need and high demand for this class of new medicines and we ask healthcare professionals to ensure that all prescriptions fall within the authorized indication.” (ANSA).
2024-04-24 19:19:03